Background/Aim: The aim of the present study was to investigate the efficacy of a
traditional Chinese medicine (TCM),
VEGFR-3 antibody-conjugated
ginsenoside Rg 3 nanoemulsion (VRIN), targeting lymphangiogenesis, on the inhibition of
tumor growth and
metastasis in an orthotopic mouse model of human
gastric cancer. Materials and Methods: An orthotopic nude-mouse model of
gastric cancer was established with the
red fluorescent protein (RFP)-expressing human
gastric cancer cell line NUGC-4-RFP. The
tumor-bearing mice were treated with vehicle (0.2 ml
normal saline every other day, iv),
5-FU (20 mg/kg once a week, i.p.) and VRIN (1 mg/kg every other day, i.v.). Real-time fluorescence imaging was performed to assess
tumor inhibition in each group.
Metastasis was evaluated by open fluorescence imaging at autopsy. The expression of lymphangiogenesis-related factors
VEGF-C, VEDF-D and
VEGFR-3 in the
tumors were analyzed by immunohistochemistry and real-time RCP. Results: VRIN and
5-FU significantly inhibited primary
tumor growth as compared to vehicle control (p<0.05). However, significant inhibition of
lymph-node metastasis was only found in the VRIN-treated group (p<0.05). The expression of
VEGF-C,
VEGF-D and
VEGFR-3 in the
tumor was suppressed by VRIN treatment (p<0.05). Expression of
VEGF-D and
VEGFR-3 in the 5-FU-treated group was not significantly increased (p>0.05). No obvious toxicity was found in VRIN- and 5-FU-treated groups. Conclusion: Lymphangiogenesis-targeted
ginsenoside Rg 3 immune-nanoemulsion inhibited
tumor growth and reduced
lymphatic metastasis by suppressing expression of
VEGF-C,
VEGF-D and
VEGFR-3 in an orthotopic mouse model of human
gastric cancer. Our study demonstrates the potential of TCM as an effective targeted treatment for metastatic
gastric cancer.